Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GCC-4001 by Artiva Biotherapeutics for Rheumatoid Arthritis: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase...
GCC-4001 by Artiva Biotherapeutics for Systemic Lupus Erythematosus: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
GCC-4001 by Artiva Biotherapeutics for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According...
GCC-4001 by Artiva Biotherapeutics for Pemphigus Vulgaris: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Pemphigus Vulgaris. According to GlobalData, Phase...
GCC-4001 by Artiva Biotherapeutics for Microscopic Polyangiitis (MPA): Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Microscopic Polyangiitis (MPA). According to GlobalData,...
GCC-4001 by Artiva Biotherapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
GCC-4001 by Artiva Biotherapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
GCC-4001 by Artiva Biotherapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...
GCC-4001 by Artiva Biotherapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...
GCC-4001 by Artiva Biotherapeutics for Follicular Lymphoma: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
GCC-4001 by Artiva Biotherapeutics for Lupus Nephritis: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase...
GCC-4001 by Artiva Biotherapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
GCC-4001 by Artiva Biotherapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...